{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:05:11Z","timestamp":1785326711945,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Combination therapy with nivolumab and ipilimumab for advanced renal cell carcinoma (RCC) may cause immune-related myocarditis; however, its incidence in this cancer type and regimen remains unknown. At our institution, we measure biomarkers, such as high-sensitivity Troponin (hsTn), and perform electrocardiograms (ECGs) and echocardiography before and every month after the initiation of this therapy, and the findings obtained and patients\u2019 symptoms are continuously monitored by physicians and pharmacists. A retrospective survey was conducted on physiological and biochemical test findings and immune-related adverse events in patients with advanced RCC who received combination therapy with nivolumab and ipilimumab between October 1, 2018 and December 31, 2023. Patients suspected of having myocarditis consulted with cardiologists. Myocarditis due to this therapy was detected in 5 of the 86 patients (5.8%) assessed using the European Society of Cardiology 2022 guidelines. There were no fatal symptoms or death due to myocarditis. The median time to the onset of myocarditis was 25\u00a0days (21\u201386\u00a0days). The early detection of myocarditis caused by this therapy requires the monitoring of changes by periodically measuring hsTn and other cardiac markers and performing ECGs and echocardiography from the early stages of administration through to the end of treatment. In addition to checking symptoms, if these abnormalities are detected and myocarditis is suspected, prompt collaboration with cardiologists is recommended. Our management strategy of care by a onco-cardiology team may contribute to the early diagnosis and treatment of myocarditis.<\/jats:p>","DOI":"10.1007\/s00262-025-03945-0","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:16:40Z","timestamp":1738689400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma"],"prefix":"10.1007","volume":"74","author":[{"given":"Maki","family":"Todo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodo","family":"Gatate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Shirotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"14","key":"3945_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"17","key":"3945_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"36","key":"3945_CR3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"3945_CR4","volume-title":"Cancer immunotherapy guidelines","author":"Japan Clinical Oncology Society","year":"2023","unstructured":"Japan Clinical Oncology Society (2023) Cancer immunotherapy guidelines, 3rd edn. Kanahara Publishing Co., Ltd","edition":"3"},{"issue":"41","key":"3945_CR5","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"issue":"4","key":"3945_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S et al (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43(4):280\u2013299. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674","journal-title":"Eur Heart J"},{"issue":"18","key":"3945_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"issue":"4","key":"3945_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"16","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 16(4):50. https:\/\/doi.org\/10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"3945_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"issue":"16","key":"3945_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755\u20131764. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"3945_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor associated myocarditis. Lancet 391:933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"issue":"12","key":"3945_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"5","key":"3945_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B et al (2023) Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 13(5):1100\u20131115. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"},{"issue":"11","key":"3945_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jcdd9110378","volume":"9","author":"R Chen","year":"2022","unstructured":"Chen R, Zhou M, Zhu F (2022) Immune checkpoint inhibitors related to cardiotoxicity. J Cardiovasc Dev Dis 9(11):378. https:\/\/doi.org\/10.3390\/jcdd9110378","journal-title":"J Cardiovasc Dev Dis"},{"key":"3945_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/diagnostics13071243","volume":"13","author":"L Zotova","year":"2023","unstructured":"Zotova L (2023) Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases. Diagnostics 13:1243. https:\/\/doi.org\/10.3390\/diagnostics13071243","journal-title":"Diagnostics"},{"issue":"21","key":"3945_CR16","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381(21):2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"issue":"10272","key":"3945_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397(10272):375\u2013386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"issue":"1","key":"3945_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"5","key":"3945_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386(5):449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"issue":"1","key":"3945_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13256-021-03097-6","volume":"15","author":"Y Miyauchi","year":"2021","unstructured":"Miyauchi Y, Naito H, Tsunemori H et al (2021) Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. J Med Case Rep 15(1):508. https:\/\/doi.org\/10.1186\/s13256-021-03097-6","journal-title":"J Med Case Rep"},{"key":"3945_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2020.101508","volume":"34","author":"T Yanase","year":"2020","unstructured":"Yanase T, Moritoki Y, Kondo H et al (2020) Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management. Urol Case Rep 34:101508. https:\/\/doi.org\/10.1016\/j.eucr.2020.101508","journal-title":"Urol Case Rep"},{"key":"3945_CR22","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158\u20133176. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.072","journal-title":"J Am Coll Cardiol"},{"key":"3945_CR23","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063\u20131093. https:\/\/doi.org\/10.1093\/ehjci\/jeu192","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"3945_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ahj.2004.11.017","volume":"150","author":"B Sievers","year":"2005","unstructured":"Sievers B, Kirchberg S, Franken U et al (2005) Visual estimation versus quantitative assessment of left ventricular ejection fraction: a comparison by cardiovascular magnetic resonance imaging. Am Heart J 150(4):737\u2013742. https:\/\/doi.org\/10.1016\/j.ahj.2004.11.017","journal-title":"Am Heart J"},{"issue":"6","key":"3945_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.ejcts.2006.02.014","volume":"29","author":"CJ Jakobsen","year":"2006","unstructured":"Jakobsen CJ, Torp P, Sloth E (2006) Assessment of left ventricular ejection fraction may invalidate the reliability of EuroSCORE. Eur J Cardiothorac Surg 29(6):978\u2013982. https:\/\/doi.org\/10.1016\/j.ejcts.2006.02.014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"3945_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamainternmed.2024.2270","volume":"184","author":"R Yagi","year":"2024","unstructured":"Yagi R, Mori Y, Goto S et al (2024) Routine electrocardiogram screening and cardiovascular disease events in adults. JAMA Intern Med 184(9):1035\u20131044. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2270","journal-title":"JAMA Intern Med"},{"key":"3945_CR27","unstructured":"Japan Society of Ningen-Dock. Electrocardiogram screening determination manual. September 30, 2013. Accessed 12 Oct 2023. https:\/\/www.ningen-dock.jp\/wp\/wp-content\/uploads\/2013\/09\/d4bb55fcf01494e251d315b76738ab40.pdf"},{"key":"3945_CR28","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Published: November 27. United States Department of Health and Human Services, National Institutes of Health \u2013 National Cancer Institute"},{"issue":"6","key":"3945_CR29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL et al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35(6):591\u2013597. https:\/\/doi.org\/10.1200\/JCO.2016.70.7398","journal-title":"J Clin Oncol"},{"key":"3945_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S et al (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 94:115\u2013125. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.012","journal-title":"Eur J Cancer"},{"key":"3945_CR31","doi-asserted-by":"publisher","unstructured":"Power JR, Dolladille C, Ozbay B, et al (2024) Predictors and risk score for immune checkpoint-inhibitor-associated myocarditis severity. medRxiv preprint. https:\/\/doi.org\/10.1101\/2024.06.02.24308336, accepted","DOI":"10.1101\/2024.06.02.24308336"},{"issue":"5","key":"3945_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.acvd.2022.03.003","volume":"115","author":"JR Power","year":"2022","unstructured":"Power JR, Alexandre J, Choudhary A et al (2022) Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis 115(5):315\u2013330. https:\/\/doi.org\/10.1016\/j.acvd.2022.03.003","journal-title":"Arch Cardiovasc Dis"},{"key":"3945_CR33","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41:1733\u20131743. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051","journal-title":"Eur Heart J"},{"issue":"5","key":"3945_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A et al (2022) Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC CardioOncol 4(5):689\u2013700. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.004","journal-title":"JACC CardioOncol"},{"issue":"1","key":"3945_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jjcc.2022.07.009","volume":"81","author":"A Furukawa","year":"2023","unstructured":"Furukawa A, Tamura Y, Taniguchi H et al (2023) Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol 81(1):63\u201367. https:\/\/doi.org\/10.1016\/j.jjcc.2022.07.009","journal-title":"J Cardiol"},{"issue":"8","key":"3945_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2217\/imt-2018-0118","volume":"11","author":"M Rahouma","year":"2019","unstructured":"Rahouma M, Karim NA, Baudo M et al (2019) Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD\/PD-L1 immunotherapy randomized clinical trials. Immunotherapy 11(8):725\u2013735. https:\/\/doi.org\/10.2217\/imt-2018-0118","journal-title":"Immunotherapy"},{"key":"3945_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2169\/internalmedicine.5412-20","volume":"60","author":"J Tanabe","year":"2021","unstructured":"Tanabe J, Watanabe N, Endo A et al (2021) Asymptomatic immune checkpoint inhibitor-associated myocarditis. Intern Med 60:569\u2013573. https:\/\/doi.org\/10.2169\/internalmedicine.5412-20","journal-title":"Intern Med"},{"issue":"4","key":"3945_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","volume":"15","author":"VH Koelzer","year":"2016","unstructured":"Koelzer VH, Rothschild SI, Zihler D et al (2016) Systemic inflamation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 15(4):13. https:\/\/doi.org\/10.1186\/s40425-016-0117-1","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3945_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/0886022X.2019.1603110","volume":"41","author":"T Tarapan","year":"2019","unstructured":"Tarapan T, Musikatavorn K, Phairatwet P et al (2019) High sensitivity Troponin-I levels in asymptomatic hemodialysis patients. Ren Fail 41(1):393\u2013400. https:\/\/doi.org\/10.1080\/0886022X.2019.1603110","journal-title":"Ren Fail"},{"issue":"1","key":"3945_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/01.CIR.0000109483.45211.8F","volume":"109","author":"JH Diris","year":"2004","unstructured":"Diris JH, Hackeng CM, Kooman JP et al (2004) Impaired renal clearance explains elevated Troponin T fragments in hemodialysis patients. Circulation 109(1):23\u201325. https:\/\/doi.org\/10.1161\/01.CIR.0000109483.45211.8F","journal-title":"Circulation"},{"issue":"12","key":"3945_CR41","first-page":"1806","volume":"91","author":"S Kiatchoosakun","year":"2008","unstructured":"Kiatchoosakun S, Sahasthas D, Wongvipaporn C et al (2008) Cardiac Troponin-T in pre-end stage kidney disease. J Med Assoc Thai 91(12):1806\u20131811","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"3945_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5507\/bp.2015.050","volume":"160","author":"N Petejova","year":"2016","unstructured":"Petejova N, Martinek A (2016) Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160(2):183\u2013194. https:\/\/doi.org\/10.5507\/bp.2015.050","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03945-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:05:03Z","timestamp":1741017903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03945-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3945"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03945-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Shirotake has received lecture fees from Ono Pharmaceutical, Bristol Myers Squibb. The other authors have no conflicts of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The present study was approved by the Clinical Ethics Committee at the International Medical Center, Saitama Medical University (approval no. 2024-005) and followed the standards of the Declaration of Helsinki and the ethical standards of the responsible committee on human experimentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"97"}}